Navigation Links
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
Date:9/26/2008

eceived feedback from the CHMP that there are no major objections remaining related to chemistry, manufacturing and controls (CMC)."

Mr. Walbert continued, "While we have satisfactorily addressed issues related to the positive benefit/risk assessment reached at the oral explanation meeting with the CHMP in January 2008, we have been invited by the CHMP to meet with SAG-O and CHMP in November to address certain open issues arising from the assessment by the Rapporteur and Co-Rapporteur. We welcome the opportunity to present to both the SAG-O and CHMP to complete the L-MTP-PE MAA review and we remain confident that L-MTP-PE provides a significant overall survival benefit for osteosarcoma patients and meets an important unmet treatment need."

With the final CHMP opinion now anticipated in November, IDM Pharma expects a final decision from the European Commission in the first quarter of 2009. If approved for Marketing Authorization by the European Commission, L-MTP-PE will be the first treatment in more than 20 years approved for patients with osteosarcoma.

In January 2008, the Company announced that, following presentation of data at an oral explanation hearing, the CHMP determined in a non-binding opinion that L-MTP-PE suggested a possible clinical benefit in terms of survival and granted the Company a clock-stop, or time extension to allow IDM Pharma additional time to respond to questions regarding the MAA. At that time, the CHMP requested clarification of the existing data in order to gain assurance about the quality of the data before drawing any final conclusions from the data presented. In addition, the Company was required to address a number of remaining questions relating to CMC.

In April 2008, the European regulatory authorities conducted an inspection of the COG to assess the quality of the overall survival data from the 2006 confirmatory database included in the Company's applications for regulatory approval, and to review GCP c
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
2. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
3. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
4. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
5. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team
9. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
10. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... GREENVILLE, S.C. , Sept. 18, 2014 /PRNewswire/ ... a $1.975 million Small Business Innovation Research (SBIR) ... (NCI), one of the 27 institutes and centers ... Over the course of the two year award, ... to address two issues at the forefront of ...
(Date:9/18/2014)... , Sept. 18, 2014  ePharmaSolutions, ... was recognized as the Disruptive Innovator of ... ePharmaONE cloud-based eClinical platform. This solution includes ... trial master file (eTMF), a remote monitoring ... ePharmaSolutions, ReferralPlus+ patient screening and matching technology. ...
(Date:9/18/2014)... S.C. , Sept. 18, 2014   3D Systems ... of the Simbionix RobotiX Mentor™ , a new robotic ... for the first time at the ERUS exhibition in ... 19 (booth #7). Robotic-assisted minimally invasive surgery represents ... demand means the needs for training for robotic surgery has ...
Breaking Medicine Technology:National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 2National Cancer Institute Awards KIYATEC Nearly $2M to Advance Predictive Cancer Diagnostics 3ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 2ePharmaSolutions Named 2014 Disruptive Innovator of the Year for its ePharmaONE eClinical Platform 33D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3
... , KALAMAZOO, Mich., Dec. 31 Stryker ... of its previously announced acquisition of Ascent Healthcare Solutions, the ... in the U.S. , "The acquisition of Ascent Healthcare Solutions ... of the most impactful programs in use at hospitals, allowing ...
... , Ruling Opens Door to Physician Assisted ... Montana Supreme Court ruled that state law does not contain ... drugs to patients. This decision endangers the lives of the ... people,s lives, the law needs to draw a clear distinction ...
Cached Medicine Technology:Stryker Completes Acquisition of Ascent Healthcare Solutions 2Montana Supreme Court Decision Endangers Most Vulnerable Citizens 2
(Date:9/18/2014)... led by Queen,s University professor Robert Campbell (Ophthalmology) has ... not helpful or necessary., Glaucoma is the most common ... 400,000 Canadians are afflicted with the disease, which is ... enough to damage the optic nerve. The optic nerve ... the brain and is a vital part of vision., ...
(Date:9/18/2014)... release is available in German . ... host strategy not to fight a pathogen tooth and nail, but ... term. One key feature of tolerance is that the disease only ... host carries a high pathogen load. , Roland Regoes, a senior ... this approach to HIV. He set about investigating whether there are ...
(Date:9/18/2014)... It is almost time to park your ... healthier and happier kids. The South Florida Hyundai Dealers ... Annual Miami Children’s Hospital 5K Run/Walk. Its title sponsor ... , The 5K will take place on Saturday August 20th. ... Coral Gables City Hall located at 405 Biltmore Way. ...
(Date:9/18/2014)... Research conducted by a team of ... has documented improved survival in patients with cancerous ... tumors along with stereotactic radiosurgery. , The study was ... (American Society for Radiation Oncology) this week in San ... radiation beams to treat tumors in the brain, delivering ...
(Date:9/18/2014)... and London. (PRWEB) September 18, 2014 ... Computer Aided Engineering software, today announced its new partnership ... be utilizing the CD-adapco simulation tool, STAR-CCM+® in the ... just announced its participation in the 35th America’s Cup ... 35th edition of the America’s Cup is sustainability, the ...
Breaking Medicine News(10 mins):Health News:Withdrawal from the evolutionary race 2Health News:Withdrawal from the evolutionary race 3Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 2Health News:South Florida Hyundai Dealers Association Proudly Support the 4th Annual Miami Children’s Hospital 5K Run/Walk this Saturday August 20th in Coral Gables 3Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 2Health News:Allegheny Health Network Study Shows Improved Survival in Patients with Metastatic Brain Cancer Who Undergo Surgical Excision Combined with Stereotactic Radiosurgery 3Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2
... studying rare genetic disorders have uncovered insights into ... when cells divide. Focusing on the cohesin complex, ... encircles chromosome pairs, scientists have discovered mutations that ... diseases called cohesinopathies. "We are learning more ...
... Israel; Seoul, South Korea, May 29, 2012 -- The ... enabled an Israeli-South Korean scientific team to conduct a genetic ... B virus (HBV) genotype C2 sequence common in Southeast Asia. ... be used as a model to study the evolution of ...
... Texas For 50 years scientists have been unsure how the ... basic innate immune responses. That mystery has now been solved, thanks ... The answers may help clear the way for a ... such as V. cholerae , but instead disable their defenses ...
... battle: Long after a cancer has been beaten into remission, it ... is unclear. New research led by Weizmann Institute scientists shows that, ... cancer recurrence is in a set of cells that do not ... survive chemotherapy. The findings, which appeared today in the journal ...
... not healthy. However, new research from the University of Copenhagen ... vitamin is not good either. The study is based on ... published in the reputed scientific Journal of Clinical Endocrinology ... calcium reach our bones, thus lessening the risk from falls ...
... , MONDAY, May 28 (HealthDay News) -- Women who work ... increasing their risk for breast cancer, Danish researchers find. ... women who describe themselves as "morning" people rather than "evening" ... of women in modern societies have night shift work," said ...
Cached Medicine News:Health News:Mutations impair childhood growth and development by disrupting organization of chromosome pairs 2Health News:16th-century Korean mummy provides clue to hepatitis B virus genetic code 2Health News:50-year cholera mystery solved 2Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Too much vitamin D can be as unhealthy as too little 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 2Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 3Health News:Night Shift Might Boost Women's Breast Cancer Risk: Study 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: